How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
51
DXCM Quote, Financials, Valuation and Earnings
Last price:
$74.03
Seasonality move
:
7.25%
Day range:
$72.66 - $73.93
52-week range:
$54.11 - $93.25
Dividend yield:
0%
P/E ratio:
40.83x
P/S ratio:
6.62x
P/B ratio:
10.50x
Volume:
4.5M
Avg. volume:
5.3M
1-year change:
-16.97%
Market cap:
$28.6B
Revenue:
$4B
EPS (TTM):
$1.80
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
DXCM
DexCom, Inc.
|
$1.3B | $0.65 | 13.59% | 79.17% | $85.19 |
|
ABT
Abbott Laboratories
|
$11.8B | $1.49 | 6.14% | 55.36% | $136.32 |
|
BLFS
BioLife Solutions, Inc.
|
$24M | $0.01 | 5.9% | -98.07% | $32.44 |
|
BSX
Boston Scientific Corp.
|
$5.3B | $0.78 | 11.57% | 76.14% | $124.41 |
|
KRYS
Krystal Biotech, Inc.
|
$106.8M | $1.61 | 35.17% | 42.95% | $276.60 |
|
TNDM
Tandem Diabetes Care, Inc.
|
$277.2M | -$0.09 | 6.15% | -78.57% | $25.95 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
DXCM
DexCom, Inc.
|
$73.36 | $85.19 | $28.6B | 40.83x | $0.00 | 0% | 6.62x |
|
ABT
Abbott Laboratories
|
$106.05 | $136.32 | $184.4B | 28.64x | $0.63 | 2.26% | 4.18x |
|
BLFS
BioLife Solutions, Inc.
|
$22.93 | $32.44 | $1.1B | -- | $0.00 | 0% | 10.97x |
|
BSX
Boston Scientific Corp.
|
$93.79 | $124.41 | $139B | 50.17x | $0.00 | 0% | 7.24x |
|
KRYS
Krystal Biotech, Inc.
|
$272.91 | $276.60 | $7.9B | 40.93x | $0.00 | 0% | 21.82x |
|
TNDM
Tandem Diabetes Care, Inc.
|
$19.11 | $25.95 | $1.3B | -- | $0.00 | 0% | 1.27x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
DXCM
DexCom, Inc.
|
48.58% | 1.837 | 9.81% | 1.33x |
|
ABT
Abbott Laboratories
|
20.25% | 0.321 | -- | 1.12x |
|
BLFS
BioLife Solutions, Inc.
|
5.52% | 0.467 | 1.69% | 3.31x |
|
BSX
Boston Scientific Corp.
|
33.99% | 0.384 | 8.31% | 0.81x |
|
KRYS
Krystal Biotech, Inc.
|
0.83% | -0.755 | 0.19% | 9.43x |
|
TNDM
Tandem Diabetes Care, Inc.
|
77.16% | 1.942 | 54.61% | 1.79x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
DXCM
DexCom, Inc.
|
$747.4M | $242.5M | 14.67% | 30.94% | 20.05% | $579.4M |
|
ABT
Abbott Laboratories
|
$6.5B | $2.4B | 10.2% | 29.06% | 20.59% | $2.3B |
|
BLFS
BioLife Solutions, Inc.
|
$17.2M | -$89K | -4.73% | -5.11% | -0.32% | $2.8M |
|
BSX
Boston Scientific Corp.
|
$3.3B | $1B | 8.19% | 12.46% | 20.55% | $1.2B |
|
KRYS
Krystal Biotech, Inc.
|
$92.1M | $41.4M | 19.74% | 19.91% | 42.31% | $38M |
|
TNDM
Tandem Diabetes Care, Inc.
|
$134.3M | -$20.1M | -31.16% | -110.24% | -8.05% | $4.2M |
DexCom, Inc. vs. Competitors
-
Which has Higher Returns DXCM or ABT?
Abbott Laboratories has a net margin of 23.47% compared to DexCom, Inc.'s net margin of 15.5%. DexCom, Inc.'s return on equity of 30.94% beat Abbott Laboratories's return on equity of 29.06%.
Company Gross Margin Earnings Per Share Invested Capital DXCMDexCom, Inc.61.8% $0.70 $5.3B ABTAbbott Laboratories57.09% $1.02 $64.2B -
What do Analysts Say About DXCM or ABT?
DexCom, Inc. has a consensus price target of $85.19, signalling upside risk potential of 16.13%. On the other hand Abbott Laboratories has an analysts' consensus of $136.32 which suggests that it could grow by 28.55%. Given that Abbott Laboratories has higher upside potential than DexCom, Inc., analysts believe Abbott Laboratories is more attractive than DexCom, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DXCMDexCom, Inc.20 3 0 ABTAbbott Laboratories14 8 0 -
Is DXCM or ABT More Risky?
DexCom, Inc. has a beta of 1.480, which suggesting that the stock is 48.047% more volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.721, suggesting its less volatile than the S&P 500 by 27.854%.
-
Which is a Better Dividend Stock DXCM or ABT?
DexCom, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 2.26% to investors and pays a quarterly dividend of $0.63 per share. DexCom, Inc. pays -- of its earnings as a dividend. Abbott Laboratories pays out 64.34% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios DXCM or ABT?
DexCom, Inc. quarterly revenues are $1.2B, which are smaller than Abbott Laboratories quarterly revenues of $11.5B. DexCom, Inc.'s net income of $283.8M is lower than Abbott Laboratories's net income of $1.8B. Notably, DexCom, Inc.'s price-to-earnings ratio is 40.83x while Abbott Laboratories's PE ratio is 28.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom, Inc. is 6.62x versus 4.18x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DXCMDexCom, Inc.6.62x 40.83x $1.2B $283.8M ABTAbbott Laboratories4.18x 28.64x $11.5B $1.8B
-
Which has Higher Returns DXCM or BLFS?
BioLife Solutions, Inc. has a net margin of 23.47% compared to DexCom, Inc.'s net margin of 2.21%. DexCom, Inc.'s return on equity of 30.94% beat BioLife Solutions, Inc.'s return on equity of -5.11%.
Company Gross Margin Earnings Per Share Invested Capital DXCMDexCom, Inc.61.8% $0.70 $5.3B BLFSBioLife Solutions, Inc.61.36% $0.01 $374.4M -
What do Analysts Say About DXCM or BLFS?
DexCom, Inc. has a consensus price target of $85.19, signalling upside risk potential of 16.13%. On the other hand BioLife Solutions, Inc. has an analysts' consensus of $32.44 which suggests that it could grow by 29.88%. Given that BioLife Solutions, Inc. has higher upside potential than DexCom, Inc., analysts believe BioLife Solutions, Inc. is more attractive than DexCom, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DXCMDexCom, Inc.20 3 0 BLFSBioLife Solutions, Inc.9 0 0 -
Is DXCM or BLFS More Risky?
DexCom, Inc. has a beta of 1.480, which suggesting that the stock is 48.047% more volatile than S&P 500. In comparison BioLife Solutions, Inc. has a beta of 1.929, suggesting its more volatile than the S&P 500 by 92.869%.
-
Which is a Better Dividend Stock DXCM or BLFS?
DexCom, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioLife Solutions, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom, Inc. pays -- of its earnings as a dividend. BioLife Solutions, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DXCM or BLFS?
DexCom, Inc. quarterly revenues are $1.2B, which are larger than BioLife Solutions, Inc. quarterly revenues of $28.1M. DexCom, Inc.'s net income of $283.8M is higher than BioLife Solutions, Inc.'s net income of $621K. Notably, DexCom, Inc.'s price-to-earnings ratio is 40.83x while BioLife Solutions, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom, Inc. is 6.62x versus 10.97x for BioLife Solutions, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DXCMDexCom, Inc.6.62x 40.83x $1.2B $283.8M BLFSBioLife Solutions, Inc.10.97x -- $28.1M $621K
-
Which has Higher Returns DXCM or BSX?
Boston Scientific Corp. has a net margin of 23.47% compared to DexCom, Inc.'s net margin of 14.91%. DexCom, Inc.'s return on equity of 30.94% beat Boston Scientific Corp.'s return on equity of 12.46%.
Company Gross Margin Earnings Per Share Invested Capital DXCMDexCom, Inc.61.8% $0.70 $5.3B BSXBoston Scientific Corp.65.31% $0.50 $35.7B -
What do Analysts Say About DXCM or BSX?
DexCom, Inc. has a consensus price target of $85.19, signalling upside risk potential of 16.13%. On the other hand Boston Scientific Corp. has an analysts' consensus of $124.41 which suggests that it could grow by 32.64%. Given that Boston Scientific Corp. has higher upside potential than DexCom, Inc., analysts believe Boston Scientific Corp. is more attractive than DexCom, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DXCMDexCom, Inc.20 3 0 BSXBoston Scientific Corp.26 1 0 -
Is DXCM or BSX More Risky?
DexCom, Inc. has a beta of 1.480, which suggesting that the stock is 48.047% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.670, suggesting its less volatile than the S&P 500 by 33.029%.
-
Which is a Better Dividend Stock DXCM or BSX?
DexCom, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom, Inc. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DXCM or BSX?
DexCom, Inc. quarterly revenues are $1.2B, which are smaller than Boston Scientific Corp. quarterly revenues of $5.1B. DexCom, Inc.'s net income of $283.8M is lower than Boston Scientific Corp.'s net income of $755M. Notably, DexCom, Inc.'s price-to-earnings ratio is 40.83x while Boston Scientific Corp.'s PE ratio is 50.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom, Inc. is 6.62x versus 7.24x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DXCMDexCom, Inc.6.62x 40.83x $1.2B $283.8M BSXBoston Scientific Corp.7.24x 50.17x $5.1B $755M
-
Which has Higher Returns DXCM or KRYS?
Krystal Biotech, Inc. has a net margin of 23.47% compared to DexCom, Inc.'s net margin of 81.15%. DexCom, Inc.'s return on equity of 30.94% beat Krystal Biotech, Inc.'s return on equity of 19.91%.
Company Gross Margin Earnings Per Share Invested Capital DXCMDexCom, Inc.61.8% $0.70 $5.3B KRYSKrystal Biotech, Inc.94.21% $2.66 $1.1B -
What do Analysts Say About DXCM or KRYS?
DexCom, Inc. has a consensus price target of $85.19, signalling upside risk potential of 16.13%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $276.60 which suggests that it could grow by 1.35%. Given that DexCom, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe DexCom, Inc. is more attractive than Krystal Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DXCMDexCom, Inc.20 3 0 KRYSKrystal Biotech, Inc.11 0 0 -
Is DXCM or KRYS More Risky?
DexCom, Inc. has a beta of 1.480, which suggesting that the stock is 48.047% more volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.705%.
-
Which is a Better Dividend Stock DXCM or KRYS?
DexCom, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom, Inc. pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DXCM or KRYS?
DexCom, Inc. quarterly revenues are $1.2B, which are larger than Krystal Biotech, Inc. quarterly revenues of $97.8M. DexCom, Inc.'s net income of $283.8M is higher than Krystal Biotech, Inc.'s net income of $79.4M. Notably, DexCom, Inc.'s price-to-earnings ratio is 40.83x while Krystal Biotech, Inc.'s PE ratio is 40.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom, Inc. is 6.62x versus 21.82x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DXCMDexCom, Inc.6.62x 40.83x $1.2B $283.8M KRYSKrystal Biotech, Inc.21.82x 40.93x $97.8M $79.4M
-
Which has Higher Returns DXCM or TNDM?
Tandem Diabetes Care, Inc. has a net margin of 23.47% compared to DexCom, Inc.'s net margin of -8.49%. DexCom, Inc.'s return on equity of 30.94% beat Tandem Diabetes Care, Inc.'s return on equity of -110.24%.
Company Gross Margin Earnings Per Share Invested Capital DXCMDexCom, Inc.61.8% $0.70 $5.3B TNDMTandem Diabetes Care, Inc.53.88% -$0.31 $582.2M -
What do Analysts Say About DXCM or TNDM?
DexCom, Inc. has a consensus price target of $85.19, signalling upside risk potential of 16.13%. On the other hand Tandem Diabetes Care, Inc. has an analysts' consensus of $25.95 which suggests that it could grow by 35.81%. Given that Tandem Diabetes Care, Inc. has higher upside potential than DexCom, Inc., analysts believe Tandem Diabetes Care, Inc. is more attractive than DexCom, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DXCMDexCom, Inc.20 3 0 TNDMTandem Diabetes Care, Inc.7 13 0 -
Is DXCM or TNDM More Risky?
DexCom, Inc. has a beta of 1.480, which suggesting that the stock is 48.047% more volatile than S&P 500. In comparison Tandem Diabetes Care, Inc. has a beta of 1.682, suggesting its more volatile than the S&P 500 by 68.218%.
-
Which is a Better Dividend Stock DXCM or TNDM?
DexCom, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom, Inc. pays -- of its earnings as a dividend. Tandem Diabetes Care, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DXCM or TNDM?
DexCom, Inc. quarterly revenues are $1.2B, which are larger than Tandem Diabetes Care, Inc. quarterly revenues of $249.3M. DexCom, Inc.'s net income of $283.8M is higher than Tandem Diabetes Care, Inc.'s net income of -$21.2M. Notably, DexCom, Inc.'s price-to-earnings ratio is 40.83x while Tandem Diabetes Care, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom, Inc. is 6.62x versus 1.27x for Tandem Diabetes Care, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DXCMDexCom, Inc.6.62x 40.83x $1.2B $283.8M TNDMTandem Diabetes Care, Inc.1.27x -- $249.3M -$21.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.7T
P/E Ratio: 65x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Buy
72
BNAI alert for Jan 29
Brand Engagement Network, Inc. [BNAI] is down 16.89% over the past day.
Buy
82
STX alert for Jan 29
Seagate Technology Holdings Plc [STX] is up 0.83% over the past day.
Buy
84
GDXU alert for Jan 29
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 12.19% over the past day.
